AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001844

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland

Identifieur interne : 001844 ( PascalFrancis/Corpus ); précédent : 001843; suivant : 001845

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland

Auteurs : Christophe Le Tourneau ; Albiruni R. A. Razak ; Christine Levy ; Valentin Calugaru ; Olivier Galatoire ; Remi Dendale ; Laurence Desjardins ; Hui K. Gan

Source :

British journal of ophthalmology [ 0007-1161 ] ; 2011.

RBID : Pascal:11-0486337

Descripteurs français

Pascal (Inist)
- Carcinome, Chimiothérapie, Médicament ciblé, Glande lacrymale, Ophtalmologie.

English descriptors

KwdEn :
- Carcinoma, Chemotherapy, Lacrimal gland, Ophthalmology, Targeted drug.

Abstract

Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0007-1161`
A02	`01`			`@0 BJOPAL`
A03		`1`		`@0 Br. j. ophthalmol.`
A05				`@2 95`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland`
A11	`01`	`1`		`@1 TOURNEAU (Christophe Le)`
A11	`02`	`1`		`@1 RAZAK (Albiruni R. A.)`
A11	`03`	`1`		`@1 LEVY (Christine)`
A11	`04`	`1`		`@1 CALUGARU (Valentin)`
A11	`05`	`1`		`@1 GALATOIRE (Olivier)`
A11	`06`	`1`		`@1 DENDALE (Remi)`
A11	`07`	`1`		`@1 DESJARDINS (Laurence)`
A11	`08`	`1`		`@1 GAN (Hui K.)`
A14	`01`			`@1 Département d'Oncologie Médicale, Institut Curie @2 Paris @3 FRA @Z 1 aut.`
A14	`02`			`@1 Department of Medical Oncology, Princess Margaret Hospital @2 Toronto, Ontario @3 CAN @Z 2 aut.`
A14	`03`			`@1 Département d'Ophtalmologie, Institut Curie @2 Paris @3 FRA @Z 3 aut. @Z 7 aut.`
A14	`04`			`@1 Département de Radiothérapie, Institut Curie @2 Paris @3 FRA @Z 4 aut. @Z 6 aut.`
A14	`05`			`@1 Département d'Ophtalmologie, Fondation Rothschild @2 Paris @3 FRA @Z 5 aut.`
A14	`06`			`@1 Austin-Ludwig Medical Oncology Department @2 Melbourne, Victoria @3 AUS @Z 8 aut.`
A20				`@1 1483-1489`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 1015 @5 354000507296570020`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 105 ref.`
A47	`01`	`1`		`@0 11-0486337`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 British journal of ophthalmology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.
C02	`01`	`X`		`@0 002B09N`
C03	`01`	`X`	`FRE`	`@0 Carcinome @5 01`
C03	`01`	`X`	`ENG`	`@0 Carcinoma @5 01`
C03	`01`	`X`	`SPA`	`@0 Carcinoma @5 01`
C03	`02`	`X`	`FRE`	`@0 Chimiothérapie @5 09`
C03	`02`	`X`	`ENG`	`@0 Chemotherapy @5 09`
C03	`02`	`X`	`SPA`	`@0 Quimioterapia @5 09`
C03	`03`	`X`	`FRE`	`@0 Médicament ciblé @5 11`
C03	`03`	`X`	`ENG`	`@0 Targeted drug @5 11`
C03	`03`	`X`	`SPA`	`@0 Medicamento dirigido @5 11`
C03	`04`	`X`	`FRE`	`@0 Glande lacrymale @5 12`
C03	`04`	`X`	`ENG`	`@0 Lacrimal gland @5 12`
C03	`04`	`X`	`SPA`	`@0 Glándula lagrimal @5 12`
C03	`05`	`X`	`FRE`	`@0 Ophtalmologie @5 13`
C03	`05`	`X`	`ENG`	`@0 Ophthalmology @5 13`
C03	`05`	`X`	`SPA`	`@0 Oftalmología @5 13`
C07	`01`	`X`	`FRE`	`@0 Traitement`
C07	`01`	`X`	`ENG`	`@0 Treatment`
C07	`01`	`X`	`SPA`	`@0 Tratamiento`
C07	`02`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 37`
C07	`02`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 37`
C07	`02`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 37`
C07	`03`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`03`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`03`	`X`	`SPA`	`@0 Cáncer @2 NM`
N21				`@1 339`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0486337 INIST
ET :	Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland
AU :	TOURNEAU (Christophe Le); RAZAK (Albiruni R. A.); LEVY (Christine); CALUGARU (Valentin); GALATOIRE (Olivier); DENDALE (Remi); DESJARDINS (Laurence); GAN (Hui K.)
AF :	Département d'Oncologie Médicale, Institut Curie/Paris/France (1 aut.); Department of Medical Oncology, Princess Margaret Hospital/Toronto, Ontario/Canada (2 aut.); Département d'Ophtalmologie, Institut Curie/Paris/France (3 aut., 7 aut.); Département de Radiothérapie, Institut Curie/Paris/France (4 aut., 6 aut.); Département d'Ophtalmologie, Fondation Rothschild/Paris/France (5 aut.); Austin-Ludwig Medical Oncology Department/Melbourne, Victoria/Australie (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	British journal of ophthalmology; ISSN 0007-1161; Coden BJOPAL; Royaume-Uni; Da. 2011; Vol. 95; No. 11; Pp. 1483-1489; Bibl. 105 ref.
LA :	Anglais
EA :	Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.
CC :	002B09N
FD :	Carcinome; Chimiothérapie; Médicament ciblé; Glande lacrymale; Ophtalmologie
FG :	Traitement; Tumeur maligne; Cancer
ED :	Carcinoma; Chemotherapy; Targeted drug; Lacrimal gland; Ophthalmology
EG :	Treatment; Malignant tumor; Cancer
SD :	Carcinoma; Quimioterapia; Medicamento dirigido; Glándula lagrimal; Oftalmología
LO :	INIST-1015.354000507296570020
ID :	11-0486337

Links to Exploration step

Pascal:11-0486337

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title>
<author><name sortKey="Tourneau, Christophe Le" sort="Tourneau, Christophe Le" uniqKey="Tourneau C" first="Christophe Le" last="Tourneau">Christophe Le Tourneau</name>
<affiliation><inist:fA14 i1="01"><s1>Département d'Oncologie Médicale, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Razak, Albiruni R A" sort="Razak, Albiruni R A" uniqKey="Razak A" first="Albiruni R. A." last="Razak">Albiruni R. A. Razak</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Oncology, Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levy, Christine" sort="Levy, Christine" uniqKey="Levy C" first="Christine" last="Levy">Christine Levy</name>
<affiliation><inist:fA14 i1="03"><s1>Département d'Ophtalmologie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Calugaru, Valentin" sort="Calugaru, Valentin" uniqKey="Calugaru V" first="Valentin" last="Calugaru">Valentin Calugaru</name>
<affiliation><inist:fA14 i1="04"><s1>Département de Radiothérapie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galatoire, Olivier" sort="Galatoire, Olivier" uniqKey="Galatoire O" first="Olivier" last="Galatoire">Olivier Galatoire</name>
<affiliation><inist:fA14 i1="05"><s1>Département d'Ophtalmologie, Fondation Rothschild</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dendale, Remi" sort="Dendale, Remi" uniqKey="Dendale R" first="Remi" last="Dendale">Remi Dendale</name>
<affiliation><inist:fA14 i1="04"><s1>Département de Radiothérapie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Desjardins, Laurence" sort="Desjardins, Laurence" uniqKey="Desjardins L" first="Laurence" last="Desjardins">Laurence Desjardins</name>
<affiliation><inist:fA14 i1="03"><s1>Département d'Ophtalmologie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gan, Hui K" sort="Gan, Hui K" uniqKey="Gan H" first="Hui K." last="Gan">Hui K. Gan</name>
<affiliation><inist:fA14 i1="06"><s1>Austin-Ludwig Medical Oncology Department</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0486337</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0486337 INIST</idno>
<idno type="RBID">Pascal:11-0486337</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001844</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title>
<author><name sortKey="Tourneau, Christophe Le" sort="Tourneau, Christophe Le" uniqKey="Tourneau C" first="Christophe Le" last="Tourneau">Christophe Le Tourneau</name>
<affiliation><inist:fA14 i1="01"><s1>Département d'Oncologie Médicale, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Razak, Albiruni R A" sort="Razak, Albiruni R A" uniqKey="Razak A" first="Albiruni R. A." last="Razak">Albiruni R. A. Razak</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Oncology, Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levy, Christine" sort="Levy, Christine" uniqKey="Levy C" first="Christine" last="Levy">Christine Levy</name>
<affiliation><inist:fA14 i1="03"><s1>Département d'Ophtalmologie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Calugaru, Valentin" sort="Calugaru, Valentin" uniqKey="Calugaru V" first="Valentin" last="Calugaru">Valentin Calugaru</name>
<affiliation><inist:fA14 i1="04"><s1>Département de Radiothérapie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galatoire, Olivier" sort="Galatoire, Olivier" uniqKey="Galatoire O" first="Olivier" last="Galatoire">Olivier Galatoire</name>
<affiliation><inist:fA14 i1="05"><s1>Département d'Ophtalmologie, Fondation Rothschild</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dendale, Remi" sort="Dendale, Remi" uniqKey="Dendale R" first="Remi" last="Dendale">Remi Dendale</name>
<affiliation><inist:fA14 i1="04"><s1>Département de Radiothérapie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Desjardins, Laurence" sort="Desjardins, Laurence" uniqKey="Desjardins L" first="Laurence" last="Desjardins">Laurence Desjardins</name>
<affiliation><inist:fA14 i1="03"><s1>Département d'Ophtalmologie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gan, Hui K" sort="Gan, Hui K" uniqKey="Gan H" first="Hui K." last="Gan">Hui K. Gan</name>
<affiliation><inist:fA14 i1="06"><s1>Austin-Ludwig Medical Oncology Department</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">British journal of ophthalmology</title>
<title level="j" type="abbreviated">Br. j. ophthalmol.</title>
<idno type="ISSN">0007-1161</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">British journal of ophthalmology</title>
<title level="j" type="abbreviated">Br. j. ophthalmol.</title>
<idno type="ISSN">0007-1161</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Carcinoma</term>
<term>Chemotherapy</term>
<term>Lacrimal gland</term>
<term>Ophthalmology</term>
<term>Targeted drug</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Carcinome</term>
<term>Chimiothérapie</term>
<term>Médicament ciblé</term>
<term>Glande lacrymale</term>
<term>Ophtalmologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0007-1161</s0>
</fA01>
<fA02 i1="01"><s0>BJOPAL</s0>
</fA02>
<fA03 i2="1"><s0>Br. j. ophthalmol.</s0>
</fA03>
<fA05><s2>95</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TOURNEAU (Christophe Le)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>RAZAK (Albiruni R. A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LEVY (Christine)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CALUGARU (Valentin)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GALATOIRE (Olivier)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DENDALE (Remi)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DESJARDINS (Laurence)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GAN (Hui K.)</s1>
</fA11>
<fA14 i1="01"><s1>Département d'Oncologie Médicale, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medical Oncology, Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Département d'Ophtalmologie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Département de Radiothérapie, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Département d'Ophtalmologie, Fondation Rothschild</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Austin-Ludwig Medical Oncology Department</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>1483-1489</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>1015</s2>
<s5>354000507296570020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>105 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0486337</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>British journal of ophthalmology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B09N</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Carcinome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Carcinoma</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Carcinoma</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Médicament ciblé</s0>
<s5>11</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Targeted drug</s0>
<s5>11</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Medicamento dirigido</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Glande lacrymale</s0>
<s5>12</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Lacrimal gland</s0>
<s5>12</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Glándula lagrimal</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Ophtalmologie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Ophthalmology</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Oftalmología</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Traitement</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Treatment</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fN21><s1>339</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0486337 INIST</NO>
<ET>Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</ET>
<AU>TOURNEAU (Christophe Le); RAZAK (Albiruni R. A.); LEVY (Christine); CALUGARU (Valentin); GALATOIRE (Olivier); DENDALE (Remi); DESJARDINS (Laurence); GAN (Hui K.)</AU>
<AF>Département d'Oncologie Médicale, Institut Curie/Paris/France (1 aut.); Department of Medical Oncology, Princess Margaret Hospital/Toronto, Ontario/Canada (2 aut.); Département d'Ophtalmologie, Institut Curie/Paris/France (3 aut., 7 aut.); Département de Radiothérapie, Institut Curie/Paris/France (4 aut., 6 aut.); Département d'Ophtalmologie, Fondation Rothschild/Paris/France (5 aut.); Austin-Ludwig Medical Oncology Department/Melbourne, Victoria/Australie (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>British journal of ophthalmology; ISSN 0007-1161; Coden BJOPAL; Royaume-Uni; Da. 2011; Vol. 95; No. 11; Pp. 1483-1489; Bibl. 105 ref.</SO>
<LA>Anglais</LA>
<EA>Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.</EA>
<CC>002B09N</CC>
<FD>Carcinome; Chimiothérapie; Médicament ciblé; Glande lacrymale; Ophtalmologie</FD>
<FG>Traitement; Tumeur maligne; Cancer</FG>
<ED>Carcinoma; Chemotherapy; Targeted drug; Lacrimal gland; Ophthalmology</ED>
<EG>Treatment; Malignant tumor; Cancer</EG>
<SD>Carcinoma; Quimioterapia; Medicamento dirigido; Glándula lagrimal; Oftalmología</SD>
<LO>INIST-1015.354000507296570020</LO>
<ID>11-0486337</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001844 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001844 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0486337
   |texte=   Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri